When was rybelsus approved?

Rybelsus (semaglutide) was first approved by the U.S. Food and Drug Administration (FDA) on September 20, 2019 for adults with type 2 diabetes to improve glycemic control, and it is the first oral GLP-1 receptor agonist approved in the U.S. [1]

When did Rybelsus get approved in other countries?

Rybelsus was approved outside the U.S. as well, but approval dates vary by regulator (for example, the EMA in Europe). If you tell me the country/region you mean, I can narrow it to the exact date.

Why does the approval date matter?

The FDA approval date is what anchors timelines tied to marketing exclusivity and patent/dispute events. Those timelines often determine when generic versions or competitors may be able to launch, which can be tracked through patent databases such as DrugPatentWatch.com [2].

Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209797s000lbl.pdf
2. https://www.drugpatentwatch.com/